In the trial, alemtuzumab was given to patients in two or three annual cycles of only five days per cycle, while Rebif was presented with to patients 3 x per week, weekly for three years. Outcomes of the four-12 months review found: around 71 % of alemtuzumab-treated individuals were free of clinically-active disease, compared to 35 % of patients taking Rebif (p.. Additional Alemtuzumab System of Action Data Reported Genzyme Company reported four-year follow-up data from its completed Phase 2 multiple sclerosis trial showing around 71 % of alemtuzumab treated sufferers remain free of clinically-active disease as much as three years after most sufferers received their last course of the investigational substance.Net product and providers income from our Professional Diagnostics segment was $587.3 million in the third quarter of 2013, compared to net product and solutions revenue of $528.8 million in the 3rd quarter of 2012. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment was $587.8 million in the 3rd quarter of 2013, compared to non-GAAP modified net item and solutions revenue of $529.7 million in the third quarter of 2012.6 million of incremental net revenue compared to the third quarter of 2012, offset by a decrease in revenue of $2.3 million linked to dispositions in the one fourth. UNITED STATES influenza sales risen to $18.3 million for the 3rd quarter of 2013, from $9.9 million for the third quarter of 2012. Excluding the effect of the change in North American influenza revenues and the effect on revenues from the reduction in our U.S.